Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (31-40 of 174) with videos related to

Pageof 18
Sort By:
Nature Reviews. Clinical Oncology|November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham Mailankody
Seminars in Hematology|October 6, 2024
Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?Sridevi Rajeeve, Abhinav Hoskote, Sham Mailankody
JAMA Oncology|June 10, 2016
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical TrialsHemanth Kumar, Tito Fojo, Sham Mailankody
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The road to treating smoldering multiple myelomaNeha Korde, Sham Mailankody, Ola Landgren
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Many Shades of Disparities in Myeloma CareSiddhartha Ganguly, Sham Mailankody, Sikander Ailawadhi
Nature Reviews. Clinical Oncology|May 16, 2018
Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham Mailankody
JAMA Oncology|July 7, 2018
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-ReplyVinay Prasad, Victoria Kaestner, Sham Mailankody
Hematology. American Society of Hematology. Education Program|December 4, 2020
Future of CAR T cells in multiple myelomaKitsada Wudhikarn, Sham Mailankody, Eric L Smith
Nature Reviews. Clinical Oncology|March 15, 2017
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Kevin De Jesús, Sham Mailankody
Hematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z Usmani
Pageof 18

Showing results (31-40 of 174) with videos related to

Sort By:
Pageof 18
Nature Reviews. Clinical Oncology|November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham Mailankody
Seminars in Hematology|October 6, 2024
Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?Sridevi Rajeeve, Abhinav Hoskote, Sham Mailankody
JAMA Oncology|June 10, 2016
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical TrialsHemanth Kumar, Tito Fojo, Sham Mailankody
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2014
The road to treating smoldering multiple myelomaNeha Korde, Sham Mailankody, Ola Landgren
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Many Shades of Disparities in Myeloma CareSiddhartha Ganguly, Sham Mailankody, Sikander Ailawadhi
Nature Reviews. Clinical Oncology|May 16, 2018
Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham Mailankody
JAMA Oncology|July 7, 2018
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies-ReplyVinay Prasad, Victoria Kaestner, Sham Mailankody
Hematology. American Society of Hematology. Education Program|December 4, 2020
Future of CAR T cells in multiple myelomaKitsada Wudhikarn, Sham Mailankody, Eric L Smith
Nature Reviews. Clinical Oncology|March 15, 2017
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Kevin De Jesús, Sham Mailankody
Hematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z Usmani
Pageof 18